AEterna Zentaris Current Ratio 2006-2021 | AEZS

AEterna Zentaris current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
AEterna Zentaris Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.08B $0.01B 16.44
2021-03-31 $0.08B $0.01B 15.68
2020-12-31 $0.03B $0.01B 5.56
2020-09-30 $0.02B $0.00B 12.98
2020-06-30 $0.01B $0.00B 3.58
2020-03-31 $0.01B $0.00B 3.46
2019-12-31 $0.01B $0.01B 1.93
2019-09-30 $0.01B $0.01B 2.34
2019-06-30 $0.01B $0.01B 1.68
2019-03-31 $0.01B $0.01B 2.38
2018-12-31 $0.02B $0.01B 2.91
2018-09-30 $0.02B $0.01B 3.64
2018-06-30 $0.02B $0.01B 4.04
2018-03-31 $0.03B $0.01B 3.68
2017-12-31 $0.01B $0.01B 1.63
2017-09-30 $0.01B $0.01B 2.32
2017-06-30 $0.02B $0.00B 3.71
2017-03-31 $0.02B $0.00B 5.60
2016-12-31 $0.02B $0.00B 5.41
2016-09-30 $0.02B $0.01B 3.98
2016-06-30 $0.03B $0.01B 5.04
2016-03-31 $0.03B $0.01B 6.46
2015-12-31 $0.04B $0.01B 6.60
2015-09-30 $0.04B $0.02B 2.13
2015-06-30 $0.05B $0.01B 8.51
2015-03-31 $0.06B $0.01B 8.80
2014-12-31 $0.04B $0.01B 4.78
2014-09-30 $0.04B $0.01B 5.99
2014-06-30 $0.04B $0.01B 7.34
2014-03-31 $0.05B $0.01B 8.39
2013-12-31 $0.05B $0.01B 6.31
2013-09-30 $0.04B $0.01B 4.22
2013-06-30 $0.04B $0.02B 1.69
2013-03-31 $0.05B $0.01B 3.33
2012-12-31 $0.05B $0.02B 3.40
2012-09-30 $0.05B $0.01B 3.12
2012-06-30 $0.05B $0.02B 3.21
2012-03-31 $0.06B $0.02B 3.48
2011-12-31 $0.06B $0.02B 3.36
2011-09-30 $0.06B $0.02B 3.76
2011-06-30 $0.06B $0.02B 3.15
2011-03-31 $0.05B $0.02B 3.02
2010-12-31 $0.04B $0.01B 3.28
2010-09-30 $0.05B $0.01B 3.53
2010-06-30 $0.06B $0.02B 3.68
2010-03-31 $0.04B $0.02B 2.52
2009-12-31 $0.05B $0.02B 2.55
2009-09-30 $0.06B $0.02B 2.37
2009-06-30 $0.07B $0.03B 2.62
2009-03-31 $0.07B $0.03B 2.82
2008-12-31 $0.06B $0.02B 2.78
2008-09-30 $0.03B $0.02B 1.50
2008-06-30 $0.04B $0.02B 1.78
2008-03-31 $0.06B $0.03B 2.19
2007-12-31 $0.06B $0.02B 2.68
2007-09-30 $0.07B $0.02B 3.60
2007-06-30 $0.07B $0.02B 4.06
2007-03-31 $0.08B $0.02B 3.96
2006-12-31 $0.10B $0.02B 6.24
2006-09-30 $0.16B $0.06B 2.48
2006-06-30 $0.16B $0.06B 2.54
2006-03-31 $0.16B $0.06B 2.75
2005-12-31 $0.16B $0.06B 2.60
2005-09-30 $0.12B $0.08B 1.64
2005-06-30 $0.13B $0.08B 1.73
2005-03-31 $0.17B $0.07B 2.30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.071B $0.004B
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76